AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cytotoxic T-lymphocyte protein 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P16410

UPID:

CTLA4_HUMAN

Alternative names:

Cytotoxic T-lymphocyte-associated antigen 4

Alternative UPACC:

P16410; A0N1S0; E9PDH0; O95653; Q0PP65; Q52MC1; Q53TD5; Q5S005; Q8WXJ1; Q96P43; Q9UKN9

Background:

Cytotoxic T-lymphocyte protein 4 (CTLA-4), also known as Cytotoxic T-lymphocyte-associated antigen 4, plays a pivotal role in the immune system as a major negative regulator of T-cell responses. Its interaction with natural B7 family ligands, CD80 and CD86, showcases a stronger affinity compared to the stimulatory coreceptor CD28, highlighting its critical function in modulating immune responses.

Therapeutic significance:

CTLA-4's involvement in diseases such as Systemic lupus erythematosus, Type 1 diabetes mellitus 12, Celiac disease 3, and Immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation underscores its potential as a therapeutic target. Understanding the role of CTLA-4 could open doors to potential therapeutic strategies, offering hope for patients suffering from these autoimmune disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.